Changes to anti-JCV antibody levels in a Swedish national MS cohort

摘要: Background The anti-JC virus (JCV) antibody status has been introduced to stratify patients with multiple sclerosis (MS) for higher or lower risk of progressive multifocal leukoencephalopathy (PML). Objective To assess the potential utility anti-JCV levels earlier diagnosis prediction PML. Methods An analytically validated assay was used determine serological status, normalised optical density values, and dilution titres antibodies. method applied stored sera 1157 MS including five cases PML, all enrolled in Swedish pharmacovigilance study natalizumab (NAT). Anticytomegalovirus (CMV) antivaricella-zoster (VZV) served as controls. Results Prior treatment NAT, were stable positive patients. During therapy, a slight decrease antiVZV levels, but not anti-CMV observed. All who developed PML showed mild moderate increase at time diagnosis; pre-PML samples suggested that this might start already prior Conclusions Treatment initiation NAT may lead anti-VZV suggestive suppressive effect on levels. Our findings demonstrate onset can be accompanied by increasing antibodies serum. Monitoring could potentially tool during MS. Further studies are warranted.